Details for Patent: 10,300,039

Which drugs does patent 10,300,039 protect, and when does it expire?

Patent 10,300,039 protects AURYXIA and is included in one NDA.

This patent has thirty-six patent family members in twelve countries.

Summary for Patent: 10,300,039

Title:	Ferric citrate dosage forms
Abstract:	Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).
Inventor(s):	Le; Henry Trong (Englewood Cliffs, NJ)
Assignee:	KERYX BIOPHARMACEUTICALS, INC. (Boston, MA)
Application Number:	15/159,008
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,300,039
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,300,039

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Keryx Biopharms	AURYXIA	ferric citrate	TABLET;ORAL	205874-001	Sep 5, 2014		RX	Yes	Yes						CONTROL OF SERUM PHOSPHORUS LEVELS

International Family Members for US Patent 10,300,039

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010276242
Brazil	112012001372
Canada	2768656
China	102573807